Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...
The new indication adds to the 2021 approval of Susvimo (ranibizumab) for 'wet' or neovascular age-related macular ...
Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...
“OCU200 has the potential to change the treatment landscape for DME, diabetic retinopathy (DR), and wet ... 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug ...
Hosted on MSN21d
From cancer to diabetic retinopathy, how AIIMS is betting big on AI to aid in diagnosticsThe app analyses the data using AI technology, providing a risk assessment of oral cancer labelled as “suspicious ... diseases like tuberculosis, diabetic retinopathy, breast cancer, leprosy ...
Detailed price information for Ocular Therapeut (OCUL-Q) from The Globe and Mail including charting and trades.
Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...
EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...
Eylea (aflibercept) is a prescription drug that treats certain eye conditions. Eylea can cause side effects that range from mild to serious. An example includes cataracts, which may become a long ...
With rumours about celebrities using semaglutide drugs like Ozempic for quick weight loss the question remains Are these anti ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback